EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitor (EGFR TKI) therapies have shown to be of great benefit to non-small cell lung cancer (NSCLC) patients harboring EGFR activating mutations, such as L858R and exon 19 deletions [1, 2].